Mycobiome Evaluation in Children With Autism & GI Symptoms

The University of Texas Health Science Center, Houston60 enrolled

Overview

This study's primary aim is to explore the potential differences in the gut mycobiome of children with autism spectrum disorder compared to otherwise healthy children. The secondary objective of this study is to evaluate whether the presence of specific species of fungi (e.g. Candida tropicalis, C. albicans, or Saccharomyces cerevisiae), in stool: 1) correlates with increased gastrointestinal symptoms; 2) correlates with evidence of increased behavioral problems (as assessed by the Aberrant Behavior Checklist or Social Responsiveness Scale-2); or 3) plays the same role as a constituent of commensal gut microflora as in normal controls. The scale indicates severity of social deficits in the autism spectrum as mild, moderate or severe. Additionally, the study aims to compare the fecal and oral fungi in these children because many fecal mycobiota are felt to originate in the oropharynx.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Autism Gastrointenstinal Symptoms

Eligibility

Sex: ALLMin age: 4 YearsMax age: 16 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * for autistic children with GI symptoms: confirmed diagnosis of autism spectrum disorder (ASD) and its severity (DSM-5: 299.00) by Autism Diagnostic Interview (ADI-R), Social Communication Questionnaire (SCQ), and Autism Diagnostic Observation SChedule-2 (ADOS-2); substantial gastrointestinal symptoms (as indicated by score of greater than 7 on the Gastrointestinal Symptoms Severity Index) * for autistic children without GI symptoms: confirmed diagnosis of autism spectrum disorder (ASD) and its severity (DSM-5: 299.00) by Autism Diagnostic Interview (ADI-R), Social Communication Questionnaire (SCQ), and Autism Diagnostic Observation SChedule-2 (ADOS-2) * for controls: healthy children Exclusion Criteria: * severe sensory impairment * brain injury * major psychiatric illness (e.g., psychotic disorders that might interfere with assessment). (however, children with common psychological problems such as depression and attention deficit hyperactivity disorder will not be excluded, given that doing so would result in a sample of children with ASD that would be unrepresentative of the pediatric ASD population as a whole.)- children who appear genetically syndromic (based on exam in the pediatric GI clinic) * taking immunosuppressive medications * abnormal screening labs * GI diseases * allergy to antibiotics * fever or a pre-existing adverse event monitored in the study * known history of hepatitis B/C or HIV * known pregnancy * use of probiotics in the last 60 d * use of oral antibiotics/anti-fungal during the previous 2 weeks * indwelling catheters/prosthetic devices

Outcomes

Primary Outcomes

Fecal Mycobiome Composition as assessed by sequencing of fecal fungal species

Time frame: day 1

Secondary Outcomes

Presence of fungal species Candida tropicalis

Time frame: day 1

Presence of fungal species Candida albicans

Time frame: day 1

Presence of fungal species Saccharomyces cerevisiae

Time frame: day 1

Gastrointentinal (GI) symptoms as assessed by the GI Symptoms Severity Index

Time frame: day 1

Behavioral problems as assessed by the Aberrant Behavior Checklist (ABC)

Time frame: day 1

Behavioral problems as assessed by the Social Responsiveness Scale-2 (SRS-2)

Time frame: day 1

Oral Mycobiome Composition as assessed by sequencing of oral fungal species

Time frame: day 1

Gut inflammation as assessed by fecal calprotectin levels

Time frame: day 1

Antifungal immunity as assessed by serum dectin 1 levels

Time frame: day 1

Mycobiome Evaluation in Children With Autism & GI Symptoms

Overview

Conditions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes

Central Contacts